Patents by Inventor Martha Karen Newell Rogers
Martha Karen Newell Rogers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230226135Abstract: The invention relates to methods for modulating the neurological and immune function through targeting of acetylcholine (ACh) and CLIP. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including psychiatric or neurological disease, autoimmune disease, transplant and cell graft rejection, chronic wounds, non-neuronal immune disorders, Alzheimer's, Parkinson's Disease, Lewy Body dementia, pediatric acute neuropsychiatric syndromes (PANS), hypertension, late stage Ebola, Hantavirus, or coronavirus-induced hyperinflammatory conditions, including infections that cause a pathological “cytokine storm”, other post-infectious syndromes that result in cytokine storms in some people, and cancer, as well as novel methods of diagnosis and of introducing a treatment regimen into a subject and improving cognition and addiction cessation methods.Type: ApplicationFiled: July 16, 2020Publication date: July 20, 2023Applicant: BCell Solutions, Inc.Inventors: Martha Karen Newell-Rogers, Evan Newell
-
Publication number: 20220265755Abstract: The invention relates to methods for modulating the neurological and immune function through targeting of acetylcholine (ACh) and CLIP. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including psychiatric or neurological disease, autoimmune disease, transplant and cell graft rejection, chronic wounds, non-neuronal immune disorders, Alzheimer's, Parkinson's Disease, Lewy Body dementia, pediatric acute neuropsychiatric syndromes (PANS), hypertension, late stage Ebola, Hantavirus, or coronavirus-induced hyperinflammatory conditions, including infections that cause a pathological “cytokine storm”, other post-infectious syndromes that result in cytokine storms in some people, and cancer, as well as novel methods of diagnosis and of introducing a treatment regimen into a subject and improving cognition and addiction cessation methods.Type: ApplicationFiled: July 16, 2020Publication date: August 25, 2022Applicant: BCell Solutions, Inc.Inventors: Martha Karen Newell-Rogers, Evan Newell
-
Publication number: 20220143128Abstract: The invention relates to methods for treating traumatic brain injury by targeting specific innate and adaptive immune responses generated after the injury. The specific innate and adaptive immune responses may be targeted, for instance, using CLIP inhibitors, MIF antagonists and CD74 cleavage inhibitors and combinations thereof.Type: ApplicationFiled: November 5, 2019Publication date: May 12, 2022Applicant: BCell Solutions, Inc.Inventor: Martha Karen Newell-Rogers
-
Publication number: 20210252102Abstract: The invention relates to methods for treating cancers by targeting the elimination of selective activated immune cell populations in combination with checkpoint inhibitors. The cells may be targeted, for instance, using CLIP inhibitors and or MHC class II inducers.Type: ApplicationFiled: April 29, 2021Publication date: August 19, 2021Applicants: The Texas A&M University System, The Regents of the University of Colorado, a Body CorporateInventors: Richard Tobin, Martha Karen Newell-Rogers
-
Publication number: 20200268831Abstract: The invention relates to methods for treating cancers by targeting the elimination of selective activated immune cell populations in combination with checkpoint inhibitors. The cells may be targeted, for instance, using CLIP inhibitors and or MHC class II inducers.Type: ApplicationFiled: September 14, 2018Publication date: August 27, 2020Applicants: The Texas A&M University System, The Regents of the University of Colorado, a Body CorporateInventors: Richard Tobin, Martha Karen Newell-Rogers
-
Publication number: 20200069766Abstract: The invention relates to methods for modulating the immune function through targeting of CLIP molecules. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including autoimmune disease, cancer, Alzheimer's disease, allergic disease, transplant and cell graft rejection, HIV infection and other viral, bacterial, and parasitic infection, and AIDS. Methods are also provided for preparing a peptide having the property of being able to displace CLIP by feeding one or more peptide sequences into software that predicts MHC Class II binding regions in an antigen sequence and related products.Type: ApplicationFiled: August 19, 2019Publication date: March 5, 2020Applicant: The Regents of the University of Colorado, a Body CorporateInventors: Martha Karen Newell-Rogers, Evan Newell
-
Patent number: 10420813Abstract: The invention relates to methods for modulating the immune function through targeting of CLIP molecules. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including autoimmune disease, cancer, Alzheimer's disease, allergic disease, transplant and cell graft rejection, HIV infection and other viral, bacterial, and parasitic infection, and AIDS. Methods are also provided for preparing a peptide having the property of being able to displace CLIP by feeding one or more peptide sequences into software that predicts MHC Class II binding regions in an antigen sequence and related products.Type: GrantFiled: August 10, 2016Date of Patent: September 24, 2019Assignee: The Regents of the University of Colorado, a Body CorporateInventors: Martha Karen Newell-Rogers, Evan Newell
-
Publication number: 20170348377Abstract: The invention relates to methods for modulating the immune function through targeting of CLIP molecules. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including autoimmune disease, cancer, Alzheimer's disease, allergic disease, transplant and cell graft rejection, HIV infection and other viral, bacterial, and parasitic infection, and AIDS. Methods are also provided for preparing a peptide having the property of being able to displace CLIP by feeding one or more peptide sequences into software that predicts MHC Class II binding regions in an antigen sequence and related products.Type: ApplicationFiled: August 10, 2016Publication date: December 7, 2017Applicant: Regents of the University of Colorado, a body corporateInventors: Martha Karen Newell-Rogers, Evan Newell
-
Patent number: 9359404Abstract: The invention relates to methods for altering biological parameters in a subject, such as reducing blood pressure in a subject, by displacing CLIP, using a CLIP inhibitor. The methods are useful for treating disorders such as preeclampsia and high blood pressure.Type: GrantFiled: November 30, 2012Date of Patent: June 7, 2016Assignees: Scott & White Healthcare, The Texas A&M University System, VG Life Sciences, Inc.Inventors: Martha Karen Newell-Rogers, Brett Mitchell, Evan Newell
-
Publication number: 20150231195Abstract: The invention relates to methods for modulating the immune function through targeting of CLIP molecules. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including autoimmune disease, cancer, Alzheimer's disease, allergic disease, transplant and cell graft rejection, HIV infection and other viral, bacterial, and parasitic infection, and AIDS. Methods are also provided for preparing a peptide having the property of being able to displace CLIP by feeding one or more peptide sequences into software that predicts MHC Class II binding regions in an antigen sequence and related products.Type: ApplicationFiled: January 29, 2015Publication date: August 20, 2015Applicant: Regents of the University of Colorado, a body corporateInventors: Martha Karen Newell-Rogers, Evan Newell
-
Publication number: 20150231237Abstract: Methods and products for treating proliferative diseases, and wounds, using as a pharmacon an autophagy inhibitor, a glycolytic inhibitor, and/or an agent able to alter cellular production of reactive oxygen, or combination thereof, optionally in combination with one or more chemotherapeutic agents. In some embodiments, the invention combines a 4-aminoquinoline, exemplified by chloroquine, with a glycolytic inhibitor, exemplified by 2-deoxy-D-glucose and anti-VEGF antibodies.Type: ApplicationFiled: May 5, 2015Publication date: August 20, 2015Applicant: The Regents of the University of Colorado, a body corporateInventors: Martha Karen Newell-Rogers, Susannah K. Rogers
-
Publication number: 20120058091Abstract: The invention is based in part on the discovery that chromosomal disorders such as Down Syndrome can be diagnosed by assessing maternal mitochondrial status. Thus the invention relates to diagnostic and therapeutic methods and related products for chromosomal disorders such as Downs Syndrome, for example, for identifying a risk of fetal Downs Syndrome and methods of mitigating that risk. The methods also are useful for other therapies where it is desirable to manipulate mitochondria such as tissue generation.Type: ApplicationFiled: March 29, 2011Publication date: March 8, 2012Applicant: The Regents of the University of ColoradoInventors: Martha Karen Newell Rogers, Elizabeth Villalobos-Menuey, Robert Melamede, Robert E. Camley
-
Publication number: 20080057039Abstract: Abstract: The invention is based in part on the discovery that chromosomal disorders such as Down Syndrome can be diagnosed by assessing maternal mitochondrial status. Thus the invention relates to diagnostic and therapeutic methods and related products for chromosomal disorders such as Downs Syndrome, for example, for identifying a risk of fetal Downs syndrome and methods of mitigating that risk. The methods also re useful for other therapies where it is desirable to manipulate mitochondria such as tissue generation.Type: ApplicationFiled: May 12, 2004Publication date: March 6, 2008Inventors: Martha Karen Newell Rogers, Elizabeth Villalobos-Menuey, Robert Melamede, Robert Camley
-
Publication number: 20040005291Abstract: The invention is based in part on the discovery that the expression of co-stimulatory molecules such as B7.1, B7.2 or CD40 can be regulated using reactive oxygen species (ROS). Thus, the invention relates to methods of regulating co-stimulatory molecules by modulating reactive oxygen. The methods and products are useful, for example, for modulating antigen specific immune responses, treating disease, and for modulating cell growth.Type: ApplicationFiled: October 15, 2002Publication date: January 8, 2004Inventors: Martha Karen Newell Rogers, Robert Camley, Charles Richard Ill, Thomas Christensen, Zbigniew Celinski, Richard Trauger, Evan Newell, Elizabeth Villalobos-Menuey